Vertex Pharmaceuticals (VRTX) to Release Quarterly Earnings on Monday

Vertex Pharmaceuticals (NASDAQ:VRTX) is set to post its quarterly earnings results after the market closes on Monday, May 6th. Analysts expect Vertex Pharmaceuticals to post earnings of $3.61 per share for the quarter. Vertex Pharmaceuticals has set its FY 2024 guidance at EPS.Investors interested in participating in the company’s conference call can do so using this link.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, topping the consensus estimate of $3.85 by $0.35. The firm had revenue of $2.52 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. During the same period last year, the business earned $3.33 earnings per share. On average, analysts expect Vertex Pharmaceuticals to post $15 EPS for the current fiscal year and $16 EPS for the next fiscal year.

Vertex Pharmaceuticals Trading Up 0.2 %

Shares of Vertex Pharmaceuticals stock opened at $401.08 on Friday. The company’s fifty day moving average price is $409.64 and its two-hundred day moving average price is $399.55. The firm has a market capitalization of $103.66 billion, a PE ratio of 28.88, a price-to-earnings-growth ratio of 1.89 and a beta of 0.39. Vertex Pharmaceuticals has a 52-week low of $320.01 and a 52-week high of $448.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.99 and a quick ratio of 3.78.

Wall Street Analysts Forecast Growth

VRTX has been the subject of several analyst reports. JPMorgan Chase & Co. raised their target price on Vertex Pharmaceuticals from $390.00 to $438.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Canaccord Genuity Group reiterated a “sell” rating and set a $371.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, April 12th. Wells Fargo & Company upped their price objective on shares of Vertex Pharmaceuticals from $500.00 to $540.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Oppenheimer reissued an “outperform” rating and issued a $500.00 target price on shares of Vertex Pharmaceuticals in a report on Monday, April 15th. Finally, Evercore ISI upgraded Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 target price for the company in a research note on Thursday, April 11th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $430.86.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, CAO Kristen Ambrose sold 1,374 shares of Vertex Pharmaceuticals stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $577,409.76. Following the completion of the sale, the chief accounting officer now owns 9,676 shares of the company’s stock, valued at $4,066,242.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Vertex Pharmaceuticals news, CAO Kristen Ambrose sold 1,374 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $577,409.76. Following the transaction, the chief accounting officer now directly owns 9,676 shares of the company’s stock, valued at approximately $4,066,242.24. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Ourania Tatsis sold 354 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $425.70, for a total transaction of $150,697.80. Following the sale, the executive vice president now directly owns 55,804 shares of the company’s stock, valued at approximately $23,755,762.80. The disclosure for this sale can be found here. Insiders have sold a total of 12,381 shares of company stock valued at $5,203,249 in the last ninety days. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.